Prevalence of endocrine disorders and their associated factors in transfusion-dependent thalassemia patients: a historical cohort study in Southern Iran
- 98 Downloads
Transfusion-dependent beta-thalassemia (TDT) patients suffer from various endocrinopathies. The main contributing factor associated with these complications is iron overload, secondary to frequent blood transfusions. To improve patients’ quality of life, we evaluated the prevalence of endocrine disorders while considering the associated factors for further assessment.
Seven hundred thirteen transfusion-dependent thalassemia patients with age range 10–62 years were enrolled in this study. Serum calcium, phosphorous, fast blood sugar, ferritin, 25-OH vitamin D, free thyroxin, thyroid-stimulating hormone and parathyroid hormone were assessed. Bone mineral density was measured by dual-energy X-ray absorptiometry.
In total, 86.8% of the TDT patients suffered from at least one endocrinopathy. The prevalence of endocrinopathies in descending order of frequency was low bone mass (72.6%), hypogonadism (44.5%), diabetes mellitus (15.9%), hypoparathyroidism (13.2%), and hypothyroidism (10.7%). Age, body mass index and splenectomy were significantly associated with most of the endocrine disorders.
Endocrine complications are frequently observed in TDT patients. Splenectomy is a major risk factor and should be generally avoided unless it is highly indicated. Periodic surveillance of endocrine function and proper management of iron overload are advised.
KeywordsEndocrinopathy Transfusion-dependent beta-thalassemia Risk factors
The author would like to thank Shiraz University of Medical Science, also the Center for Development of Clinical Research of Namazee Hospital. The authors wish to thank Mr. H. Argasi at the Research Consultation Center (RCC) of Shiraz University of Medical Sciences for his invaluable assistance in editing this manuscript.
Compliance with ethical standards
Conflict of interest
None of the authors has financial disclosures or any conflict of interest to be declared.
Research involving human participants and/or animals
This article does not contain any studies with animals performed by any of the authors.
Informed consent was obtained from all individual participants included in the study.
- 5.De Sanctis V, Soliman AT, Elsedfy H, Skordis N, Kattamis C, Angastiniotis M et al (2013) Growth and endocrine disorders in thalassemia: the international network on endocrine complications in thalassemia (I-CET) position statement and guidelines. Indian J Endocrinol Metab 17(1):8CrossRefPubMedPubMedCentralGoogle Scholar
- 9.De Sanctis V, Al Jaouni SK, Elsedfy H, Karimi M, Mousa S, Soliman AT et al (2015) Selected highlights of the IX international symposium of clinicians for endocrinopathies in Thalassemia and adolescent medicine (ICET-A) on growth, and endocrine complications in Thalassaemia. Rivista Italiana di Medicina dell’Adolescenza-Volume 13(1):1–13Google Scholar
- 11.Introduction: Standards of Medical Care in Diabetes-2018 (2018) Diabetes Care 41(Suppl 1):S1–S2Google Scholar
- 18.Pollak RD, Rachmilewitz E, Blumenfeld A, Idelson M, Goldfarb AW (2000) Bone mineral metabolism in adults with β-thalassaemia major and intermedia. Br J Haematol 111(3):902–907Google Scholar
- 30.De Sanctis V, Elsedfy H, Soliman AT, Elhakim IZ, Kattamis C, Soliman NA et al (2016) Clinical and biochemical data of adult thalassemia major patients (TM) with multiple endocrine complications (MEC) versus TM patients with normal endocrine functions: a long-term retrospective study (40 years) in a tertiary care center in Italy. Mediterr J Hematol Infect Dis 8(1):e2016022CrossRefPubMedPubMedCentralGoogle Scholar
- 35.Cappellini M-D, Cohen A, Porter J, Taher A, Viprakasit V (2014) Guidelines for the management of transfusion dependent thalassaemia (TDT): thalassaemia. International Federation Nicosia, Cyprus, pp 174–175Google Scholar
- 45.Rehim MH, Mustafa S, Rizvi SKA (2017) Correlation between serum TSH and serum ferritin in patients of beta thalassemia major. Pak J Med Health Sci 11(1):266–269Google Scholar
- 47.Jaruratanasirikul S, Wongcharnchailert M, Laosombat V, Sangsupavanich P, Leetanaporn K (2007) Thyroid function in β-thalassemic children receiving hypertransfusions with suboptimal iron-chelating therapy. J Med Assoc Thail 90:1798–1802Google Scholar
- 49.Azami M, Parizad N, Sayehmiri K (2016) Prevalence of hypothyroidism, hypoparathyroidism and the frequency of regular chelation therapy in patients with thalassemia major in Iran: a systematic review and meta-analysis study. Iran J Pediatr Hematol Oncol 6(4):261–276Google Scholar